📅 PUBMED DAILY TRIAGE — 2026-06-21
Window: 2026-06-20T09:00:00Z → 2026-06-21T09:00:00Z (CRDT) Topics scanned: 9 watchlist + 1 sentinel | Articles reviewed: 21 unique PMIDs (13 w/ abstract, 8 esummary) | Candidates evaluated: 19 scored High priority: 2 | Standard: 9 | Low/archive: 2 | Unsolicited finds: 2 Run status: PARTIAL_SUCCESS (sentinel PMID 42322124 not fetched — all watchlist topics complete)
🔴🟠 HIGH PRIORITY (8+) — Best Finds by Topic
T1 · Hematologic Malignancies (AML, MDS, CLL, MPN, Lymphoma)
TR-2026-06-21-001 / PMID 42322115 · Ibrutinib in early stage CLL: Genetic risk factors and treatment outcome in the GCLLSG CLL12 trial · 8/10 🟢 NEAR_TERM_IMPLEMENTABLE
Genetic substudy of CLL12 RCT (n=515, 69-month follow-up) published in Blood: ibrutinib improves EFS in U-IGHV, del(11q), +12, NOTCH1, ATM, NFKBIE subgroups but confers zero benefit in del(17p)/TP53-mutated early-stage CLL and no OS benefit in any subgroup — confirming watch-and-wait as standard while enabling precision genetic stratification for clinical decisions. Riecke A, Tausch E et al. (Ulm/Cologne). DOI: 10.1182/blood.2025032806
💡 Unsolicited Sentinel Find (HIGH)
TR-2026-06-21-002 / PMID 42322147 · The prognostic value of tumour budding for survival in stage II and III colorectal cancer: a systematic review and meta-analysis · 8/10 🟢 NEAR_TERM_IMPLEMENTABLE
Largest meta-analysis to date on tumour budding (43 studies, n=17,831): high-grade TB independently predicts worse DFS (HR 2.53), OS (HR 2.40), and CSS (HR 3.37) across both stage II and III CRC — supporting routine histopathological TB assessment for adjuvant therapy risk stratification. Shu Y, Nagtegaal ID et al. (Radboud UMC / Univ. Bern). Histopathology. DOI: 10.1111/his.70225
🟢⚪ STANDARD (5–7) — Top by Topic
T1 · Hematologic Malignancies
TR-2026-06-21-003 / PMID 42322117 · Aberrant splicing of MBD1 reshapes the epigenome to drive convergent myeloerythroid defects in MDS · 7/10 · Treatment Innovation
MBD1-L is a mutation-independent splice isoform (driven by ↓WTAP) that drives MDS pathology across genotypes; nanoparticle-ASO correction restores erythroid differentiation in primary human MDS samples. Blood (Princess Margaret / McMaster).
TR-2026-06-21-008 / PMID 42322062 · Next Generation Digital Morphology: Blast Preclassification in Bone Marrow Aspirates · 4/10 · Diagnostics
Review: deep learning achieves >90% sensitivity/specificity for PB smear blast detection, but BMA performance is variable; ICSH recommends prudence before routine clinical adoption. Int J Lab Hematol.
T2 · CBC-Based Diagnostics & ML in Hematology
- TR-2026-06-21-008 / PMID 42322062 · (same article as T1 above) · 4/10
T2 zero-HIGH streak: Day 3
T3 · Early Cancer Detection (Liquid Biopsy, ctDNA, cfDNA)
No high-priority finds today (best candidate scored 0/10 — zero results in 24h CRDT window)
T3 zero-HIGH streak: Day 3
T4 · AI/ML in Clinical Diagnostics & Imaging
TR-2026-06-21-006 / PMID 42321983 · Scenario-based multi-parametric QC for quality control of complex algorithms used in clinical care · 5/10 · Diagnostics
MPQC framework for patient-safe monitoring of clinical ML algorithms (illustrated with NSCLC immunotherapy prediction model mSTOP); fills AI governance gap in clinical labs. Clin Chem Lab Med. Netherlands Cancer Institute.
TR-2026-06-21-011 / PMID 42322051 · Gene delivery for cerebral neurodegenerative disorders — current advancements and limitations · 4/10 · Drug Development
Review of AAV/ASO CNS gene therapy; peripheral T4 match via ML-guided capsid design mention. Mol Ther. Ocugen.
T4 zero-HIGH streak: Day 3 | Note: 42322137 (Astrobiology AI paper) was a false positive — excluded.
T5 · Precision Oncology & Genomic Medicine
- TR-2026-06-21-010 / PMID 42322026 · Longitudinal Associations Between Inflammation and Multi-Dimensional Fatigue up to 2 Years After Colorectal Cancer Diagnosis · 4/10 · Public Health
Observational study; peripheral match (biomarker + cancer). Abstract not fetched. Int J Cancer.
T5 zero-HIGH streak: Day 3 (watchlist esearch only; 42322147 HIGH was sentinel-sourced)
T6 · Novel Therapeutics: Immunotherapy, CAR-T, Targeted Therapy
TR-2026-06-21-005 / PMID 42322125 · Expression of the High Affinity Neurotensin Receptor Defines an Immune-cold, Poor-prognosis Colorectal Cancer Subtype · 7/10 · Treatment Innovation ⚪ PROMISING_PRELIMINARY
NTSR1 is an independent poor-prognosis marker in CRC; NTSR1 antagonist SR48692 reverses spatial T-cell exclusion in 3D spheroid models — novel strategy for converting immune-excluded MSS-CRC to immunotherapy-responsive. Ann Surg. Univ. Kentucky.
TR-2026-06-21-007 / PMID 42322055 · A Self-Immunoregulatory Nanosensitizer for Sonodynamic Cancer Therapy · 5/10 · Drug Development
POR-BG@Alb suppresses SDT-induced immune resistance (PD-L1/CD47 upregulation via AMPK/c-MYC) and extends median survival 17→44 days in mouse xenografts. Adv Mater. [Non-human only; capped at 5]
TR-2026-06-21-009 / PMID 42322170 · Engineered Neutrophils in Translational Medicine: Gene Editing, Nanotechnology, and AI-Driven Clinical Breakthroughs · 4/10 · Treatment Innovation
Landscape review of CRISPR/nanotech-engineered neutrophil therapeutics; no new primary data. Adv Healthc Mater.
TR-2026-06-21-006 / PMID 42321983 · (also T6 via immunotherapy prediction use case) · 5/10
T6 zero-HIGH streak: Day 4 (best today 7/10, NTSR1 CRC — STANDARD)
T7 · Cardiovascular-Metabolic: GLP-1, SGLT2, Cardiometabolic Risk
No relevant results today (1 false-positive match: Apelin-13 COVID-19 study, LOW)
T7 zero-HIGH streak: Day 4
T8 · Aging, Longevity & Population Health
No results in 24h window (humans[MeSH] filter applied)
T8 zero-HIGH streak: Day 4
T9 · Rare Diseases with High Unmet Need
No results in 24h window
T9 zero-HIGH streak: Day 1 (reset yesterday by PMID 42318512 TK2 deficiency HIGH)
💡 UNSOLICITED FINDS
TR-2026-06-21-002 / PMID 42322147 (already highlighted as HIGH above) Tumour budding meta-analysis in CRC — sentinel find with HIGH signal; conceptually maps to T5 (Precision oncology/diagnostics biomarker). Score 8/10. 🟢 NEAR_TERM_IMPLEMENTABLE.
TR-2026-06-21-004 / PMID 42322189 · A randomized controlled trial comparing non-selective versus selective TIRADS-based cytology in thyroid cancer diagnostics · 7/10 · Diagnostics 🟢 NEAR_TERM_IMPLEMENTABLE
First RCT of EU-TIRADS for thyroid nodule FNA selection (n=195, 4 Swedish hospitals): selective TIRADS-based biopsy increases Bethesda IV-VI yield (26% vs 13%) without missing cancer, but safe FNA omission rate is smaller than expected. Br J Surg. Dahlberg J, Muth A et al. DOI: 10.1093/bjs/znag076
📊 TODAY'S BREAKDOWN
By research category:
- Genomics/Precision Medicine: 2 (42322115, 42322117)
- Diagnostics: 4 (42322147, 42322062, 42321983, 42322189)
- Treatment Innovation: 3 (42322125, 42322170, 42322051)
- Drug Development: 2 (42322055, 42322051)
- Public Health: 1 (42322026)
By evidence maturity:
- Validated: 3 (42322115, 42322147, 42322189)
- Exploratory: 8 (all others)
- Potentially Practice-Changing: 0
By watchlist topic (reviewed / kept ≥4 / highest score):
| Topic | Raw | Reviewed | Kept (≥4) | Highest |
|---|---|---|---|---|
| T1 Hematologic malignancies | 3 | 3 | 3 | 8 ✅ |
| T2 CBC/ML hematology | 1 | 1 | 1 | 4 |
| T3 Liquid biopsy | 0 | 0 | 0 | — |
| T4 AI/ML diagnostics | 4 | 4 | 2 | 5 |
| T5 Precision oncology | 2 | 2 | 1 | 4 |
| T6 Novel therapeutics | 4 | 4 | 4 | 7 |
| T7 Cardiometabolic | 1 | 1 | 0 | 3 (FP) |
| T8 Aging/longevity | 0 | 0 | 0 | — |
| T9 Rare diseases | 0 | 0 | 0 | — |
| Sentinel | 29→10 | 9/10 | 4 | 8 ✅ |
By source type: peer_reviewed 11 | preprint 0
Topics with zero 8+ articles this run (watchlist esearch only): T2, T3, T4, T5, T6, T7, T8, T9
🔧 RUN NOTES
- PARTIAL_SUCCESS status: Sentinel PMID 42322124 not fetched (budget cap reached after 9/10 sentinel candidates reviewed; all 9 watchlist topics fully covered).
- T2 zero-HIGH streak Day 3: T2 returned only 1 result today (42322062, 4/10 review). Recommendation: Try expanding T2 query to include 'automated hematology analyzer'[tiab] OR 'white blood cell count'[tiab] and monitoring over 2 more days before query revision.
- T3 zero-HIGH streak Day 3: Zero results in 24h CRDT window. No 48h window expansion triggered (total relevant records across run >5). Next run: if T3 remains zero, consider expanding to 48h window per run config.
- T6 zero-HIGH streak Day 4: T6 queries returning reviews and preclinical material. Recommendation: Add journal quality filter to T6 (e.g., NOT (Cureus[journal] OR Discov Oncol[journal])) and require Phase I/II or clinical cohort terms.
- T7 zero-HIGH streak Day 4: 42322090 is a false positive (COVID-19 apelin study likely matched 'cardiometabolic' in abstract). Recommendation: Add explicit GLP-1/SGLT2 qualifier enforcement — require at least one specific drug/class term AND cardiovascular or metabolic outcome term.
- T8 zero-HIGH streak Day 4: humans[MeSH] filter still yielding zero results in 24h window. Recommendation: Try without humans[MeSH] and apply post-filter to titles; new records may lack MeSH indexing.
- Astrobiology false positive (42322137): T4 AI query too broad — matched 'AI' in Astrobiology journal. Recommendation: Add 'clinical'[tiab] OR 'patient'[tiab] OR 'hospital'[tiab] qualifier to T4 query.
- Unsolicited sentinel HIGH: PMID 42322147 (tumour budding meta-analysis, Histopathology) scored 8/10 — sentinel continues to be productive.
- Rolling 7-day zero-HIGH streak view (from state): T6 (4 days), T7 (4 days), T8 (4 days) are the longest persistent zero-HIGH streaks — query refinement warranted for all three.
- 2 Telegram alerts sent for TR-2026-06-21-001 (CLL12 ibrutinib genetics) and TR-2026-06-21-002 (tumour budding CRC meta-analysis).